 "pharma, labs, research, medical, healthcare")
The leading names of the Indian pharmaceutical industry said that the target of touching a $130 billion size for the Indian drug industry by 2030 would not be possible without focus on innovation. India is a leading player globally when it comes to generic or copy cat drugs, but has failed to move up in the value chain when it comes to innovative drugs.
Speaking at the Global Innovation Summit 2021, Dilip Shanghvi, managing director of Sun Pharmaceuticals, the largest domestic drug maker by market share, said that they expect to touch a turnover of $1.5 billion from innovative products
